GlassScriptPhysician profile
Roberta J Hindenlang
NPI 1487746095
$1,305.68
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $55.01 · 2023: $295 · 2024: $513 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $131.87 | 2024 | Evoque |
| Abbvie INC. | $128.66 | 2021-2024 | |
| Glaxosmithkline, LLC. | $127.77 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $103.40 | 2021-2024 | Otezla, Repatha |
| Abbott Laboratories | $95.06 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $93.70 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novo Nordisk INC | $89.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $72.67 | 2023-2024 | |
| Lilly USA, LLC | $70.59 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $69.52 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $68.58 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.25 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $32.12 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $27.82 | 2024 | Voquezna |
| Cranial Technologies, INC | $25.69 | 2024 | Doc Band |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23.92 | 2021 | |
| Biogen, INC. | $20.51 | 2021 | |
| Viatris Specialty LLC | $17.48 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $15.27 | 2023 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $13.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Hindenlang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.